BioSpring Biotechnology Company
BioSpring GmbH is a contract manufacturing organization (CDMO) for the biotechnology and pharmaceutical industries based in Frankfurt.
History
[edit]
BioSpring was founded in 1997 by Hüseyin Aygün and Sylvia Wojczewski, then doctoral students at the University of Frankfurt. The headquarters and production facility are located in Frankfurt-Fechenheim, and the company remains owner-managed and independent. Since January 2022, BioSpring has been expanding into the neighboring city of Offenbach am Main, where new production facilities are being built.[1][2]
The company employs approximately 650 people from 38 nations.
Production
[edit]The active ingredients produced by BioSpring offer approaches for the treatment of previously incurable diseases, including cardiovascular diseases, neurodegenerative diseases, and cancer.[3][4][5] The company specializes in the production and analysis of nucleic acids. These molecules, which are similar in structure to the building blocks of genetic material, are used in diagnostics, research, and as active ingredients in medicine. BioSpring is a producer, in particular, of components of the CRISPR/Cas9 technology, which is used in cell and gene therapy.
Nucleic acid drugs manufactured by BioSpring
[edit]- Antisense oligonucleotides (ASOs)
- Small interfering RNA (siRNA)
- Antisense Oligonukleotide (ASOs)
- Small interfering RNA (siRNA)
- Guide RNA für CRISPR/Cas-Systeme
- mRNA- und Aptamer-Wirkstoffe
References
[edit]- ^ "Expansion in Offenbach: 30.000 weitere Quadratmeter für Bio-Spring" (in German). 2022-12-17. Retrieved 2025-01-13.
- ^ "Biotech-Shootingstar Biospring expandiert in Offenbach" (in German). 2022-12-16. Retrieved 2025-01-13.
- ^ "BioSpring hosts event on "Genome Editing – Medicine of the Future" in Frankfurt". Retrieved 2025-01-13.
- ^ "Am Puls der medizinischen Revolution" (in German). 2024-02-09. Retrieved 2025-01-13.
- ^ "BioSpring and Pantherna agree on strategic cooperation in the field of genome editing". Retrieved 2025-01-13.